Moreover, beyond NSCLC, aberrant EGFR signaling also manifests in colorectal cancer and head and neck cancer.[38] Patients with EGFR overexpression in colorectal and head and neck cancers are commonly treated with the EGFR monoclonal antibody cetuximab. This evidence concerns the gene EGFR and non-small cell lung carcinoma.